Patent assignee · US · UNIVERSITY

Sanford-Burnham Medical Research Institute

100Patents
95Active
100Granted
57Portfolio score

Filing activity: Jul 7, 2000 → Jan 4, 2021 · 45 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US7964402B2 Methods for culture and production of single cell populations of human embryonic stem cells Chemistry; Metallurgy 46 Active
US8188080B2 VHR protein tyrosine phosphatase inhibitors, compositions and methods of use Chemistry; Metallurgy 13 Active
US8367621B2 Methods and compositions related to internalizing RGD peptides Chemistry; Metallurgy 9 Active
US7935785B2 Selective substrates for matrix metalloproteinases Chemistry; Metallurgy 9 Active
US7927816B2 Methods for identifying modulators of apoptosis Physics 9 Active
US10001622B2 Multifunction autofocus system and method for automated microscopy Electricity 8 Active
US8188220B2 Methods and compositions related to targeting wounds, regenerating tissue, and tumors Human Necessities 8 Active
US9546174B2 Inhibitor of apoptosis protein (IAP) antagonists Emerging Cross-Sectional Technologies 8 Active
US8470780B2 Methods and compositions related to targeting wounds, regenerating tissue, and tumors Human Necessities 8 Active
US8753604B2 Methods and compositions for synaphically-targeted treatment for cancer Performing Operations; Transporting 7 Active
US7750134B2 Nucleic acids encoding microbial SUMO protease homologs Emerging Cross-Sectional Technologies 6 Expired
US8178104B2 Methods and compositions for targeting gC1qR/p32 Physics 6 Active
US9868707B2 Small molecule agonists of neurotensin receptor 1 Chemistry; Metallurgy 5 Active
US10227561B2 Methods and compositions for targeting progenitor cell lines Chemistry; Metallurgy 5 Active
US8119693B2 Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification Human Necessities 5 Active
US10047119B2 Inhibitor of apoptosis protein (IAP) antagonists Emerging Cross-Sectional Technologies 4 Active
US8937193B2 Apogossypolone derivatives as anticancer agents Emerging Cross-Sectional Technologies 3 Active
US8598316B2 Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies Human Necessities 3 Active
US9061079B2 Peptides that home to atherosclerotic plaques and methods of use Human Necessities 3 Active
US8785499B2 Targeting NAD biosynthesis in bacterial pathogens Human Necessities 3 Active
US8686003B2 Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification Human Necessities 3 Active
US8536132B2 Lymphatic zip codes in tumors and pre-malignant lesions Physics 3 Active
US9522198B2 Methods and compositions related to targeting tumors and wounds Chemistry; Metallurgy 3 Active
US11382880B2 Method for improving digestive health Human Necessities 3 Active
US8912136B2 Methods and compositions related to clot-binding compounds Human Necessities 3 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.